Tarsus Pharmaceuticals (TARS) Amortizatization of Intangibles (2022 - 2026)

Tarsus Pharmaceuticals' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $849000.0 for Q1 2026.

• On a quarterly basis, Amortizatization of Intangibles fell 35.39% year-over-year to $849000.0 in Q1 2026; TTM through Mar 2026 was $5.0 million, a 4.2% decrease from a year earlier, with the FY2025 full-year figure at $5.5 million, up 30.12% from the prior year.
• Amortizatization of Intangibles eased to $849000.0 in Q1 2026 per TARS's latest filing, from $925000.0 in the prior quarter.
• Across five years, Amortizatization of Intangibles topped out at $1.7 million in Q2 2025 and bottomed at $63000.0 in Q3 2022.
• The 5-year median for Amortizatization of Intangibles is $1.1 million (2024), against an average of $1.0 million.
• Across the five-year window, Amortizatization of Intangibles sank 90.02% in 2023 and jumped 1084.8% in 2024, its largest moves.
• Year by year, Amortizatization of Intangibles stood at $1.3 million in 2022, then sank by 90.02% to $125000.0 in 2023, then soared by 1084.8% to $1.5 million in 2024, then slumped by 37.54% to $925000.0 in 2025, then retreated by 8.22% to $849000.0 in 2026.
• Per Business Quant, the three latest TARS Amortizatization of Intangibles figures stand at $849000.0 (Q1 2026), $925000.0 (Q4 2025), and $1.5 million (Q3 2025).